Generic Exclusivity On Delisted Patents Upheld By Appeals Court
This article was originally published in The Pink Sheet Daily
Executive Summary
In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.
You may also be interested in...
Teva Sues FDA To Relist Risperdal Patent
J&J scenario differs from Merck's Zocor fight, attorney tells “The Pink Sheet” DAILY.
Teva Sues FDA To Relist Risperdal Patent
J&J scenario differs from Merck's Zocor fight, attorney tells “The Pink Sheet” DAILY.
Teva And Ranbaxy Launch Generic Zocor With 180-Day Exclusivity
Despite an eleventh-hour suit by Sandoz, FDA approved the generic companies’ ANDAs for simvastatin.